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Background: Stereotactic navigation techniques aim to enhance treatment precision and
safety in minimally invasive thermal ablation of liver tumors. We qualitatively reviewed and
quantitatively summarized the available literature on procedural and clinical outcomes after
stereotactic navigated ablation of malignant liver tumors.
Methods: A systematic literature search was performed on procedural and clinical
outcomes when using stereotactic or robotic navigation for laparoscopic or
percutaneous thermal ablation. The online databases Medline, Embase, and Cochrane
Library were searched. Endpoints included targeting accuracy, procedural efficiency, and
treatment efficacy outcomes. Meta-analysis including subgroup analyses was performed.
Results: Thirty-four studies (two randomized controlled trials, three prospective cohort
studies, 29 case series) were qualitatively analyzed, and 22 studies were included for
meta-analysis. Weighted average lateral targeting error was 3.7 mm (CI 3.2, 4.2), with all
four comparative studies showing enhanced targeting accuracy compared to free-hand
targeting. Weighted average overall complications, major complications, and mortality
were 11.4% (6.7, 16.1), 3.4% (2.1, 5.1), and 0.8% (0.5, 1.3). Pooled estimates of primary
technique efficacy were 94% (89, 97) if assessed at 1–6 weeks and 90% (87, 93) if
assessed at 6–12 weeks post ablation, with remaining between-study heterogeneity.
Primary technique efficacy was significantly enhanced in stereotactic vs. free-hand
targeting, with odds ratio (OR) of 1.9 (1.2, 3.2) (n = 6 studies).
Conclusions: Advances in stereotactic navigation technologies allow highly precise and
safe tumor targeting, leading to enhanced primary treatment efficacy. The use of varying
definitions and terminology of safety and efficacy limits comparability among studies,
highlighting the crucial need for further standardization of follow-up definitions.
Keywords: liver neoplasms, ablation techniques, stereotaxic techniques, computer-assisted therapies, minimally
invasive surgical proceduresSeptember 2021 | Volume 11 | Article 7136851
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Thermalablation therapy is a validatedcurative-intended treatment
option formalignant liver tumors,mainlyhepatocellular carcinoma
(HCC) and liver metastases from colorectal cancer (CRLM) (1, 2).
Following encouraging oncological outcome results for small
tumors in the setting of limited disease, thermal ablation has been
introduced into international treatment guidelines for both HCC
and CRLM (3, 4).
The key advantage of ablative treatments is their tissue-sparing
nature, allowing preservation of a maximum of functioning liver
tissue and favouring combination with a minimally invasive
treatment access to further reduce procedure-related morbidity.
The main challenge in achieving treatment success in such
minimally invasive environments is the accurate and safe
positioning of ablation probes to acquire adequate ablation
volumes with full tumor coverage (5, 6). The use of (contrast-
enhanced) ultrasound (US) imaging allows dynamic intraoperative
tumor visualization and instrument guidance both in surgical and
interventional radiology settings (7–9). For lesions remaining
invisible due to small size, deep central location, obstructing gas/
ribs, or changes in liver parenchyma (10), computed tomography
(CT) or magnetic resonance (MR) guidance enhances visibility but
introduces constraints due to radiation exposure (11) or procedure-
related complexity. Especially for tumors requiring complex
targeting trajectories, such as in the liver dome or caudal lobe, a
safe and efficient targeting is often precluded (12, 13).
To improve tumor accessibility, targeting accuracy, and
treatment safety, stereotactic navigation systems have been
introduced for use in minimally invasive surgery. These aim to
enhance treatment precision by integrating computer assistance
with imaging data, allowing stereotactic guidance of surgical
instruments (14). Over the last two decades, increasing clinical
experience with commercially available navigation devices has
been reported, including several summary articles highlighting
their main advantages (15–21). However, no systematic review of
the available literature on the clinical application of this
technology exists, and the true impact on procedural and
clinical outcomes remains unknown. The aim of this study was
to critically review and quantitatively summarize the available
literature on targeting accuracy, procedural efficiency, and
treatment efficacy when using stereotactic or robotic navigation
technology for thermal ablation of malignant liver tumors in a
minimally invasive setting.METHODS
Search Strategy
This study was conducted following the Preferred Reporting
Items for Systematic reviews and Meta-Analyses (PRISMA)
guidelines (22). The PRISMA checklist is available as
Supplementary File 1. A systematic literature review was
performed on May 20, 2020, searching the online databases
Medline, Embase, and the Cochrane Central Register of
Controlled Trials for all available full-text articles. Search terms
were organized according to the population, intervention,Frontiers in Oncology | www.frontiersin.org 2comparison, and outcomes (PICO) criteria, without including
comparison or outcome criteria to keep the search as broad as
possible. Given the expected paucity of published literature, no
limitation of publication dates was applied. The complete search
strategy is shown in Table 1.
Study Selection
Eligible studies included original articles on adults, reporting on
procedural or clinical outcomes when using stereotactic or
robotic guidance for targeting and thermal ablation of
malignant liver tumors, and using a minimally invasive
(laparoscopic or percutaneous) approach. Stereotactic or
robotic guidance was defined as the utilization of a tracked
ablation probe or aiming device for targeting and subsequent
therapeutic thermal ablation. Included studies reported on one
or more of the following outcomes related to stereotactic thermal
ablation of liver tumors: i) targeting accuracy, ii) procedural
efficiency and safety, and iii) treatment efficacy. Excluded were
i) review articles, ii) conference abstracts, iii) studies focusing on
image fusion without the use of a tracked ablation probe or
aiming device for tumor targeting, iv) studies analyzing efficacy
of combined transarterial chemoembolization (TACE) and
stereotactic ablation of liver tumors, v) case reports defined
as <10 patients treated with navigated/robotic ablation, and
vi) full texts written in languages other than English.
Two authors (PT and JE) independently determined
eligibility for each citation by sequential review of titles,
abstracts, and full texts using the predefined criteria. In case of
disagreements, consensus was reached by group discussion.
Reference lists from included studies were reviewed for
additional citations not identified by the original search.
Covidence (23) and Mendeley were used for screening and
reference citation management.
Data Extraction and Risk of
Bias Assessment
All data extracted for systematic review and meta-analysis were
entered into a data spreadsheet available as [Supplementary File
2]. Main outcomes were i) targeting accuracy, defined as
targeting errors resulting after stereotactic ablation probe
positioning; ii) procedural efficiency and safety, including
duration of the overall procedure and of stereotactic ablation
probe positioning, numbers of probe readjustments, radiation
exposure reported as dose length product (DLP), hospital length
of stay (LOS), and clinical complications; and iii) treatment
efficacy, including rates of technical success, primary and
secondary technique efficacy, and local tumor progression
(LTP). Definitions of treatment efficacy were summarized
using the standardized terminology and reporting criteria for
image-guided tumor ablation (24). The authors’ detailed
descriptive definitions of all endpoints are available in the
[Supplementary File 2].
For quantitative analyses, data from studies with overlapping
patient populations were obtained from the most relevant
publications. These were chosen by prioritizing studies with
the largest sample size and then by studies published most
recently. Risk of bias in individual studies was evaluated for allSeptember 2021 | Volume 11 | Article 713685
Tinguely et al. Stereotactic Ablation of Liver Tumorsoutcomes according to the ROBINS-I tool (25), and studies with
high risk of bias were excluded from meta-analysis. Studies
reporting on ablation for uncommon subpopulations of liver
tumors (i.e., very large tumors) were considered high risk of
selection bias toward safety and efficacy outcomes. Comparative
observational studies reporting outcomes without matching of
tumors with respect to targeting complexity (e.g., tumor
location) were considered medium risk of bias due to
confounding. No quantitative analyses were performed for
efficiency outcomes (probe readjustments, procedure, and
targeting durations/DLP) and LTP, since heterogeneity across
studies in definition and assessment of these outcomes was
deemed too important.
Data Synthesis and Meta-Analysis
Baseline characteristics were summarized, and weighted
averages, rates, and odds ratios (ORs) were reported according
to individual number of lesions or patients, as appropriate.
Pooled estimates were calculated based on a modified inverse
variance method, applying a continuous/binary random effects
model given the assumed heterogeneity of included studies
(DerSimionian–Laird method) (26). To avoid skewing of the
variance toward zero, an arcsine transformation was applied for
outcomes with small reported proportions (major complications,
mortality) (27). Subgroup meta-analysis was performed to account
for known sources of heterogeneity due to differing definitions for
complication rates and primary technique efficacy. Between-study
heterogeneity was reported as I2 statistic and chi-square test of
homogeneity. Sensitivity analyses were performed by comparing
results from subgroup analyses vs. overall results and random-
effects vs. fixed-effects analyses. OpenMetaAnalyst (28), R (R Core
Team, 2019), and RStudio (RStudio Inc., USA) were used for meta-
analysis and generation of graphics.RESULTS
After screening a total of 1,412 articles, 93 original works published
in English and reporting on a minimum of 10 patients treated with
stereotactic or robotic thermal ablation for malignant liver tumorsFrontiers in Oncology | www.frontiersin.org 3were included for full-text screening. After additional exclusion of
59 works, 34 articles were included for qualitative analysis and 22
for quantitative analysis (Figure 1).
All of the 34 included works were single-center studies, of
which 26 were retrospective studies (29–54), three were
prospective case series (55–57), three were prospective cohort
studies (58–60), and two were randomized controlled trials (61,
62). Two studies reported results using a laparoscopic treatment
access (36, 55); the other 32 reporting on thermal ablations using
a percutaneous approach. Six studies applied robotic targeting
using mechanical tracking (39–41, 44, 60, 62), seven an
electromagnetic (EM)-tracked dynamic technique (34, 43, 51,
55, 57, 59, 61), and the other 21 an optically tracked stereotactic
aiming device. Baseline study, patient and lesion characteristics,
applied ablation and navigation techniques, and reported
outcomes of the included works are shown in Table 2. All data
extracted from included studies are available in the
Supplementary File 2. Results from meta-analyses including
sensitivity analyses and selection bias assessment are available in
Supplementary File 3.
The published literature on stereotactic or robotic guidance
for thermal ablation of liver tumors increased continuously since
the first clinical series in 2011. This was the case regarding all
reported endpoints and most prominently for safety and
treatment efficacy, as illustrated in Figure 2.
Targeting Accuracy
Of the 34 included studies, 10 reported on targeting accuracy, of
which nine reported Euclidean, lateral, or angular targeting
errors after stereotactic ablation probe positioning. The
remaining study reported a 95.6% targeting accuracy, defined
as the center of the ablated zone being located within a 5-mm
range from the preoperatively defined ideal target point, as
assessed on a 24-h CT/MRI scan (43). Pooled estimates for
Euclidean, lateral, and angular targeting errors were 5.3 (95% CI
3.9, 6.7), 3.7 (3.0, 4.4), and 2.4 (1.7, 3.1) mm, respectively, with
significant between-study heterogeneity (Table 3). Summary
estimates for lateral targeting errors are displayed in Figure 3.
Three studies investigated factors influencing targeting
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regression. Mauri et al. (43) showed no influence on “correct
targeting” by tumor entity, lesion characteristics, and applied
guidance and ablation techniques. Widmann et al. (56) found
larger lateral errors at the ablation probe tip in lesions located in
“subphrenic plus fat” as opposed to “clear parenchymal”
positions and in Segment II vs. Segment IV. Tinguely et al.
(29) reported statistically significant higher lateral targeting
errors with raising targeting trajectory lengths (0.2 mm per
additional cm) and when targeting tumors in cirrhotic livers
(by 0.7 mm) in a multivariable model, with no influence of
challenging lesion locations or complex targeting trajectories
on accuracy.
Procedural Efficiency and Safety
Eighteen studies reported on procedural efficiency, and all
included works reported on safety related to stereotactic
targeting for thermal ablation. The need for readjustment of
ablation probes due to insufficient accuracy was reported
varyingly across studies. Four studies reported mean numbers
of ablation probe readjustments of n = 0 (62), 0.8 (40), 1.1 (60),
and 2.4 (61). Nine authors reported relative numbers of probe
readjustments per patient [4.8% (51), 5.6% (58), 35% (44), andFrontiers in Oncology | www.frontiersin.org 460% (40)] or per lesion [1% (29), 4% (37), 5.6% (58), 8.8% (55),
and 41.2% (39)]. Mean overall procedure duration ranged between
18.3 and 254.5 min in 12 studies and navigated targeting duration
between 1.5 and 36.3 min in eight reporting studies. Mean total
DLP ranged between 807 and 2,216 mGy * cm in 11 studies
reporting overall radiation exposure. Hospital length of stay
ranged between 0 and 7 days in 18 reporting studies.
All included studies reported on treatment-related
complications, applying varying types of definitions. Twelve
studies used the definitions proposed by the Society of
Interventional Radiology (SIR) (63), eight applied the Clavien–
Dindo classification (64), two applied the definitions proposed
by Ahmed et al. (24), one applied the CIRSE classification, and 11
studies used other definitions or did not further specify. The
overall complication rate ranged between 0% and 57.9%, the
pooled estimate being 11.4% (CI 6.7, 16.1; I2 87.9%, p < 0.01) in
16 studies included for meta-analysis. Major complications
ranged between 0% and 20.5%, the 20.5% rate being reported
in a study of patients undergoing stereotactic radiofrequency
ablation (RFA) for very large (≥8 cm) tumors (49). The overall
pooled estimate for major complication rate was 2.4% (CI 1.4,
3.6; I2 20.7%, p = 0.198), which was lower in the subgroup
applying the Clavien–Dindo classification (2.0%; CI 0.7, 4.0) vs.FIGURE 1 | Flowchart of study selection after systematic literature review.September 2021 | Volume 11 | Article 713685
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Tinguely et al. Stereotactic Ablation of Liver TumorsFIGURE 2 | Distribution of reported endpoints over time (n = 34 studies).TABLE 3 | Summary of targeting accuracy.
Study, year published Euclidean error [mm] Lateral error [mm] Angular error [°]
TinguelyA, 2020 (29) 2.9 ± 2.3 2.0 ± 1.2
Volpi, 2019 (51) 22 ± 19°
Heerink, 2019 * (62) 10.2 ± 5.2 6.4 ± 4.2 4.5 ± 3.2
BeyerA, 2018 (58) 3.7 ± 1.2 2.8 ± 1.3 2.7 ± 1.5
Engstrand, 2016 (37) 5.8 ± 3.2 4.0 ± 2.5 2.7 ± 2.9
BeyerB, 2015 (39) * # 3.1 ± 2.5
Mbalisike, 2014 (60) * # 5.3 ± 1.8
WidmannB, 2011 (56) 3.6 ± 2.5 1.3 ± 1.2
Pooled estimates (95% CI) 5.3 (3.9, 6.7) 3.7 (3.0, 4.4) 2.4 (1.7, 3.1)
Heterogeneity (I^2, p-value) (92.6%, <0.001) (75.3%, 0.003) (83.9%, <0.001)Frontiers in Oncology | www.frontiersin.org 7 September 2021 | Volume 1* Robotic guidance.
# Only accuracies of initial probe placements are shown (before eventual re-adjustments).
Only accuracies of initial probe placements are shown (before eventual readjustments).
° Defined as “first-pass control”: aiming at approximately 1 cm from the tumor. Not included in weighted average.FIGURE 3 | Forest plot for pooled estimate of lateral targeting error.1 | Article 713685
Tinguely et al. Stereotactic Ablation of Liver Tumorsthe subgroup applying the SIR classification (4.0%; CI 1.0, 8.8)
(Figure 4). Mortality rates ranged between 0% and 4.3%, with a
pooled estimate of 0.8% (CI 0.4, 1.4; I2 0%, p = 0.99) in 20 studies
included for meta-analysis.
Treatment Efficacy
Thirty-oneof the34 included studies reportedontreatment efficacy.
Varying definitions were reported for all treatment efficacy
outcomes, including the time points for assessment and the
duration of follow-up. Six studies (29, 33, 34, 41, 46, 61) referred
to the terminology for follow-up assessment after ablation of liver
tumors proposed by Ahmed et al. (24), while 13 studies applied
similar definitions without explicitly referencing this classification.
Individual descriptions and time points of follow-up assessments
are available for each study in the Supplementary File 2. Varying
time points and durations of follow-up assessments in studies
reporting treatment efficacy are illustrated in Figure 5.
Keeping in mind this variability in definitions as well as the
varying specific inclusion criteria for patients and lesions in
several studies [e.g., very large tumors ≥8 cm (49), vanishing
lesions (30)], reported rates for technical success ranged from
90.2% to 100% (18 studies), for primary technique efficacy from
80.5% to 100% (27 studies) and for secondary technique efficacy
from 90.2% to 100% efficacy (13 studies), and for LTP from 0% to
54% (21 studies). Quantitative analysis of primary technique
efficacy (i.e., complete tumor ablation at the first follow-up
imaging) according to time points of the first follow-up is
summarized in Figure 3. Primary technique efficacy rates were
reported to be higher in studies performing a first follow-up after
1–6 weeks (pooled estimate 93.6%; CI 88.9, 97.1) than in studies
assessing primary technique efficacy at 6–12 weeks (pooled
estimate 90.1%; CI 87.2, 92.7). Despite subgroup analysis, a
statistically significant between-study heterogeneity remained in
the former group (Figure 6).Frontiers in Oncology | www.frontiersin.org 8Six studies presented analyses on factors influencing
treatment efficacy when using stereotactic tumor targeting, four
of which included multivariable regression analyses. Tinguely
et al. (29) showed a statistically significant influence of tumor size
(</>3 cm) and targeting accuracy (</>5 mm) on LTP, with no
influence by more complex intrahepatic tumor locations, in a
multivariable model accounting for clustering by using
Generalized Estimating Equation (GEE). Schaible et al. (41)
reported tumor size (</>3 cm) next to the type of targeting
approach (stereotactic vs. free-hand) to be a significant predictor
of primary technique efficacy in a similar logistic GEE model.
Lachenmayer et al. (33) found vessel proximity and tumor size
(</>3 cm) as independent predictors for LTP. Hirooka et al. (59)
reported the free-hand as opposed to the stereotactic approach to
be significantly associated with “local residual recurrence” in Cox
regression analysis. In univariable between-group comparisons,
Widmann et al. (47) reported differences in “technique
effectiveness” for lesion size </>5 cm and hollow viscera
vicinity and no differences for tumor entity and lesion location.
Bale et al. (45) found differences in “local recurrence” rates for
lesions in proximity to vessels, bile ducts, and hollow organs.Comparative Studies
Nine studies compared stereotactic vs. “free-hand” ablation for
varying endpoints, including two randomized controlled studies
(61, 62) and three prospective cohort studies (59, 60) of which
one used matched-pair analysis (58). Main study characteristics
and reported results for targeting accuracy, procedural efficiency,
and safety and treatment efficacy are summarized in Table 4.
Targeting accuracy was shown to be significantly enhanced
when using stereotactic targeting in three out of four studies [one
of them after manual adaptation of the ablation probe (39)]. The
randomized controlled trial by Heerink at al (62). confirmedFIGURE 4 | Forest plot for pooled estimates of major complication rates according to definitions of morbidity.September 2021 | Volume 11 | Article 713685
Tinguely et al. Stereotactic Ablation of Liver Tumorsenhanced accuracy specifically for out-of-plane trajectories
(5.9 vs. 10.1 mm) and showed a significant reduction of
ablation probe repositionings in robotic vs. free-hand ablations
(0 vs. 1, primary study endpoint). This was confirmed by Zhang
et al. (61) showing fewer instrument readjustments (2.4 vs. 4.95)
when using EM-guided targeting and by Mbalisike et al. (60)
when using robotic as opposed to conventional CT guidance (1.1
vs. 3 readjustments).
Durations for overall procedures and for ablation probe
positionings were reported variably across studies. Zhang et al.
(61) showed a significant reduction in the number of CT scans
used for interventions (7 vs. 10), in CT fluoroscopy time, and in
total DLP when using EM-guided as opposed to free-hand
targeting. Four other studies showed a reduction, and two
studies showed an increase in total DLP in the stereotactic vs.Frontiers in Oncology | www.frontiersin.org 9free-hand cohort using (Table 2). In the RCT of Heerink et al.
(62), the number of navigational CT scans tended to be lower in
stereotactic vs. free-hand procedures (5 vs. 7), and the increase in
DLP was presumably due to the larger scan field necessary to
include the optical reference fiducials.
With respect to treatment efficacy, Zhang et al. (34) showed a
higher complete ablation rate in the first session (3 days after
ablation) when using stereotactic EM guidance but equal
primary technique efficacy at 1 month. All six studies included
for meta-analysis assessed primary technique efficacy at a first
follow-up imaging between 1 and 6 weeks. Stereotactic and
robotic guidance led to enhanced primary technique efficacy
rates as opposed to free-hand targeting, with a pooled OR of 1.94
(CI 1.18, 3.19) (Figure 7). Sensitivity analyses comparing
random- to fixed-effects analysis showed comparable results,FIGURE 5 | Definitions and time points of reported follow-up assessments.FIGURE 6 | Forest plot of pooled odds ratio of primary technique efficacy after stereotactic vs. free-hand targeting.September 2021 | Volume 11 | Article 713685
TABLE 4 | Comparison of stereotactic vs. free-hand ablation targeting for thermal ablation.
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Tinguely et al. Stereotactic Ablation of Liver Tumorsand the risk of publication bias was nonsignificant for this result
(Egger’s test: t = -1.24, p = 0.2840) (Supplementary File 3).
Four propensity score matched analyses compared
stereotactic thermal ablation for different subtypes of patients
or lesions. Stereotactic RFA yielded similar safety and treatment
efficacy outcomes when comparing CT “invisible” tumors
ablated with MR image fusion to CT-visible tumors (30),
octogenarians to a younger study population (52), lesions in a
subphrenic location to non-dome locations (31), and HCC in a
subcardiac position to a non-subcardiac location (32).DISCUSSION
This work is a summary of the currently published knowledge on
procedural and clinical benefits of applying minimally invasive
stereotactic and robotic navigation technology for thermal
ablation of malignant liver tumors. To our knowledge, this is
the first systematic review and meta-analysis on this topic.
Stereotactic navigation technologies for use in liver surgery aim
to enhance precision when performing tissue-sparing treatments
such as “atypical” resections not following standard anatomical
landmarks or locally targeted interventions such as thermal
ablations. For the latter case specifically, the aims are to i) ensure
adequate oncological results in a minimally invasive setting by
precise ablation probe positioning and ii) enhance safety by
defining trajectories that avoid injury to critical anatomical
structures. Stereotactic navigation systems enable quantification
of the accuracy with which ablation probes are positioned by
measuring the error between the planned “optimal” and the final
“real” probe position. This facilitates the intraoperative decision
regarding an eventual probe readjustment and, importantly, allows
a reproducible and comparable evaluation of targeting success. As
summarized herein, pooled estimates for targeting accuracy in over
650 targeted lesions ranged from 2.4 to 5.3 mm, with relatively
small confidence intervals and with all comparative studies
showing reduced targeting errors as compared to free-hand
techniques (Table 4).
The pooled estimates for major complication rates for different
definitions ranged between 1.8% and 5.2%, as expected when
applying tissue-sparing treatments in a minimally invasive setting.
Importantly, the number of probe readjustments was significantly
reduced in three comparative studies, including two randomized
controlled trials. This decrease in liver punctures until reaching
adequate probe positions toward n = 1 represents an importantFrontiers in Oncology | www.frontiersin.org 11virtue of stereotactic thermal ablation, leading to enhanced safety
(60, 62). It further allows to safely target a multitude of tumors in
one treatment session (average number of tumor targeted in
included studies up to 6; Table 2), keeping oncological
indications for ablation treatment in mind. The high efficiency in
tumor targeting did not unanimously translate into reduced overall
procedure durations, where confidence intervals were wide and
conflicting results were reported in comparison to free-hand
targeting. An increased complexity in hardware setup and
procedural workflows has been highlighted as potential drawbacks
when using such novel technology (40). One way to optimize
procedural efficiency when applying such novel technology is to
invest in initial training of staff including anesthesia to create
smooth and standardized clinical workflows in multidisciplinary
teams. The latter allow relatively steep learning curves (36) and a
reduction of inter-operator variance as a factor influencing
outcomes after thermal ablation (47). The present study confirms
enhanced reliability and reproducibility of outcomes as being one of
the key advantages of using stereotactic ablation techniques (50).
Overall reported treatment efficacy rates were encouraging,
leading to increased early local tumor control when using
stereotactic navigation as opposed to manual guidance as shown
in the latest available comparative studies (Figure7).Of importance
is the inconsistency in reported definitions describing technique
efficacy and LTP (Figure 5). While standardized terminology and
reporting of outcomes criteria after image-guided ablation have
been proposed (24), definitions allow wide ranges of author-
dependent interpretations. Especially the definition of “secondary
treatment efficacy” allows for differing and unspecified numbers of
retreatments over an undefined follow-up period to be included.
Consequently, detectable tumor at the ablation site might only be
defined as “local tumor progression” rates at 6 or 12 months after
the initial ablation. This renders a straightforward comparison of
reported results impossible. Despite subgroup meta-analysis
according to time point of follow-up, subgroups remained highly
heterogeneous due to variations in included patients, lesions, and
applied types of stereotactic ablative treatments. This highlights the
need for further standardization of follow-up definitions toward
more clearly defined ranges of follow-up time points and more
precise terminology. Using novel segmentation technology, a
quantitative volumetric assessment of ablation margins will in the
future allow a quantified distinction between “incomplete ablation”
and true “tumour recurrence/progression at the ablation site” (65).
Integrating such precise assessment of treatment success into
refined follow-up terminology could contribute to the generationFIGURE 7 | Forest plot for pooled estimates of primary technique efficacy rates according to time points of first follow-up.September 2021 | Volume 11 | Article 713685
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thermal ablation.
Varying types of navigation modalities were applied in
the included studies, such as optically tracked aiming devices or
EM-tracked ablation probes combined with US to CT/MR image
fusion. An upcoming group of navigation systems uses robotic
assistance devices, relying on mechanical tracking for automatic
orientation of the robotic arm but still requiring manual insertion of
ablation probes. These comprise important but only initial steps
toward automation and standardization of stereotactic ablation on a
larger scale. Future generations of robotic devices aim to perform
automated probe positioning according to defined trajectories (66)
and generate individualized ablation volumes for specified tumor
configurations (67). The development of automated and dynamic
patient tracking will further allow to address current challenges
related to motion artifacts and facilitate ablation under sedation. No
clear benefit regarding targeting accuracy when using current
robotic vs. non-robotic approaches can be confirmed to date.
A potential limitation of the present work involves a potential
bias in interpretation of qualitative analyses due to overlapping
cohorts (Figure 1), which was not feasible to address, since studies
overlapped varyingly for different outcomes assessed. Another
important issue is the heterogeneity in tumor entities and applied
ablation systems in the included studies, since variability in the
response to applied ablation energies across tumor types and devices
is known (68, 69). In this study, we deliberately focused on targeting
accuracy, procedural efficiency, and primary technique efficacy,
which were not expected to differ significantly between tumor
types, since they are primarily related to procedural technique
rather than oncological aspects. Contrarily, many tumor-specific
determinants affect ablation site recurrences and long-term tumor
control, such as satellite nodules detectable on pathology but not
imaging, underlying liver disease, mutational status and location of
primary tumor, and different types and time points of
chemotherapy regimens (70, 71). Lastly, combination therapies
with other interventional treatments complicate comparisons of
long-term oncological outcomes. A variability in the calculation of
morbidity and mortality rates (assessment per patient vs. per
intervention vs. per lesion, 30- vs. 90-day period) remained. In
some studies, it was further unclear if the positioned ablation
probes, for which targeting accuracies were reported, were the
ones applied for subsequent thermal ablation. This might affect
conclusions regarding a relationship of targeting accuracy with
resulting treatment efficacy. While accurate tumor targeting is the
initial step for successful ablation, an independent correlation with
early ablation site recurrence has been described (29).
As technology evolves, it can be expected that stereotactic and
robotic interventions will increasingly become an integral part of the
multimodality management of malignant liver tumors. Due to the
increasing expertise in specialized centers, treatment indications for
stereotactic thermal ablation are increasingly expanded. The present
summary shows the encouraging results in all reported outcomes
including for patients with tumors in difficult intrahepatic locations
[centrally, liver dome (31), segment 1 (53)], very large tumors (49),
and “vanishing” or CT-invisible tumors using image fusion (72). In
practice, minimally invasive stereotactic ablation approaches areFrontiers in Oncology | www.frontiersin.org 12beneficial especially in these situations, where they allow a curative
intended treatment when conventional image guidance techniques
preclude an efficient and safe targeting. Key challenges remaining to
be addressed when using current navigation technology are
potential inaccuracies due to motion artifacts (73) and concerns
regarding cost effectiveness (74).
CONCLUSIONS
Advances in stereotactic navigation technology allow highly
precise, safe, and efficient minimally invasive ablation of
malignant liver tumors, potentially leading to enhanced early
treatment efficacy compared to traditional guidance techniques.
Heterogeneity in terminology and time points in follow-up
assessment limits comparability of safety and treatment efficacy
among studies, highlighting the crucial need for further
standardization and guidelines for follow-up definitions.
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